GLP-1 Before Surgery: When to Stop, ASA Anesthesia Guidance

GLP-1 receptor agonists slow gastric emptying. That is part of how they work for weight and glucose — and it is also why anesthesiologists worry about them before surgery. Multiple retrospective studies (Silveira 2023^[5], Wu 2024^[6]) found that patients on semaglutide still had solid food in the stomach after a standard overnight fast, raising the risk of pulmonary aspiration during anesthesia. In 2023 the American Society of Anesthesiologists issued consensus-based guidance (Ushakumari 2024 Anesthesiology^[1]) recommending a 1-week hold for weekly GLP-1 drugs and a 24-hour hold for daily drugs before elective procedures. In 2024 the ASMBS, AGA, ASA, ASGE, IFSO, and SAGES published joint multisociety guidance (Kindel 2024^[2], Hashash 2024^[3]) refining that framework. This article walks through what the evidence shows and the practical perioperative protocol it implies for patients on Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, and Rybelsus.

The honest summary

• Weekly drugs: hold 1 week before elective procedures under anesthesia or deep sedation. Per the ASA 2023 consensus (Ushakumari 2024^[1]), patients on semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), or compounded weekly GLP-1s should skip the dose the week of surgery so the last injection is at least 7 days before the procedure.
• Daily drugs: hold 24 hours. Liraglutide (Saxenda, Victoza) and oral semaglutide (Rybelsus) have shorter half-lives; the ASA recommends skipping the dose on the day of surgery.
• Emergency surgery: do not delay. Treat as full stomach. Rapid-sequence induction, head-up positioning, and consideration of gastric ultrasound before induction are the recommended mitigations.
• Residual gastric content is real even with the recommended hold. Santos 2024^[7] reported residual solid content in roughly 30% of patients held 24 hours, dropping to roughly 12% at 7 days and 8% at 14 days — vs ~5% baseline in GLP-1-naive controls. The 1-week hold reduces but does not eliminate the risk.

Why GLP-1s matter to the anesthesia team

GLP-1 receptor agonists delay gastric emptying as part of their mechanism of action. In the trial datasets that underpin Wegovy and Zepbound approvals, gastric-emptying T50 (the time to empty half of a standardized meal) was roughly doubled at steady state. That effect is dose dependent and persists for as long as the drug is at therapeutic levels. For weekly semaglutide and tirzepatide the elimination half-life is approximately 5–7 days, which is why the ASA chose a 1-week hold — one half-life after the last dose — as the working threshold (Ushakumari 2024^[1]).

The clinical concern is pulmonary aspiration of gastric contents during anesthesia induction. Standard preoperative fasting guidelines (NPO after midnight, or 6 hours for solids and 2 hours for clear liquids) assume normal gastric emptying. When emptying is delayed, the stomach is not empty at induction and aspiration risk rises. The original red flag came from Silveira 2023^[5] — a retrospective Brazilian series that found roughly a quarter of patients on semaglutide who arrived for elective upper endoscopy after standard NPO had visible solid food in the stomach.

What Silveira 2023 actually showed

Silveira and colleagues^[5] reviewed records from a single ambulatory endoscopy unit and compared residual gastric content on EGD between patients on semaglutide and matched controls. Among 404 patients, those on semaglutide had residual solid food in the stomach at a substantially higher rate than the comparison group despite identical preoperative fasting instructions. The finding was replicated in larger cohorts: Wu 2024^[6], a historical cohort study from a Massachusetts academic center, found GLP-1 RA therapy was independently associated with the presence of gastric contents at endoscopy after adjustment for diabetes, obesity, and other gastroparesis risk factors. Singh 2024^[4] reviewed the endoscopy-specific literature and concluded that the signal is consistent across study designs.

What the ASA 2023 guidance actually says

The ASA Task Force statement (Ushakumari and Sladen 2024 Anesthesiology^[1]) is consensus-based rather than RCT-derived. The key recommendations:

• Weekly dosing: hold for at least one week before elective procedures requiring general anesthesia, deep sedation, or moderate sedation that may compromise airway protection.
• Daily dosing: hold for at least 24 hours before the procedure.
• Day of procedure: ask every patient about GLP-1 use during the preoperative interview, and reassess gastrointestinal symptoms on the day of surgery. Significant nausea, vomiting, abdominal distension, or dyspepsia suggests delayed emptying regardless of how long ago the dose was taken.
• If hold was incomplete: options include delaying the procedure, treating the patient as a full stomach with rapid-sequence induction, or proceeding with pre-induction gastric ultrasound to assess residual volume.
• Emergent surgery: do not delay; manage as full stomach with appropriate airway protection.
• Diabetes considerations: patients with type 2 diabetes who hold GLP-1 therapy need a glucose management plan during the hold period. Coordination with the prescribing clinician about bridging therapy is recommended.

The 2024 multisociety refinement

Kindel and colleagues^[2] — representing the ASMBS, AGA, ASA, ASGE, IFSO, and SAGES — published a joint clinical practice guidance in 2024 that accepted the ASA framework but added context. The multisociety statement emphasizes that:

• The aspiration-risk signal from observational data is real but the absolute risk of clinically significant aspiration remains low.
• Blanket holds may cause harm in patients using GLP-1s for diabetes — loss of glycemic control and DKA risk in some type 1 or insulin-dependent type 2 patients.
• A 24-hour clear-liquid diet before the procedure may be a reasonable alternative or adjunct to the 1-week hold, particularly for patients in whom dose interruption is undesirable.
• Symptom assessment on the day of surgery is at least as important as the prior dose interval. A patient who held for 7 days but is still nauseated should be treated as full stomach.

The AGA Rapid Clinical Practice Update (Hashash 2024 Clinical Gastroenterology and Hepatology^[3]) focuses specifically on endoscopy and reaches the same basic conclusion: hold weekly drugs 1 week and daily drugs on the day of the procedure, but assess symptoms and consider gastric ultrasound when the timing is uncertain.

Magnitude: residual gastric content by hold duration

Procedure categories: who needs what hold

General anesthesia, elective

The default. Weekly drug holds for 1 week; daily drug holds for 24 hours. Examples: cholecystectomy, hysterectomy, joint replacement, hernia repair, non-emergent vascular surgery, elective C-section.

Deep sedation for procedures (EGD, colonoscopy, bronchoscopy)

Treated the same as general anesthesia because airway protection is compromised. Endoscopy is the setting where residual gastric content was first documented (Silveira 2023^[5]) and where the gastroenterology societies have been most explicit about the hold (Hashash 2024^[3], Singh 2024^[4]).

Moderate sedation (e.g. screening colonoscopy with minimal sedation)

Same framework but with more flexibility if the airway is not at risk. Many endoscopy centers default to the full 1-week hold for consistency.

Spinal or regional anesthesia only

Lower aspiration risk because the airway is preserved. Most guidance still recommends the standard hold because intraoperative conversion to general anesthesia is always possible and an unprotected airway over a full stomach is the worst-case scenario.

Local anesthesia only (e.g. skin biopsy, minor ophthalmologic procedures, dental work)

Hold not required. Patient remains conscious with intact airway reflexes.

Emergency surgery

Do not delay. Treat as full stomach: rapid-sequence induction with cricoid pressure, head-up positioning, and consider pre-induction gastric ultrasound (point-of-care ultrasound to assess antral content) if expertise and equipment are available.

Bariatric surgery: a special case

The ASMBS-led multisociety guidance^[2] specifically addresses bariatric surgery candidates. Many patients are on a GLP-1 as a pre-surgical bridge or as primary therapy that is being escalated to surgery. The recommendation is to discontinue weekly GLP-1s at least 1 week before the operative date, with some bariatric programs extending to 2 weeks to ensure a fully empty stomach at induction. Restart timing depends on the operation and the patient's tolerance of an oral diet. See our companion piece on GLP-1 as a bariatric surgery bridge for the bridging decision framework.

Pregnancy and Caesarean delivery

GLP-1s are contraindicated in pregnancy. Patients planning pregnancy should discontinue the drug at least 8 weeks before conception per the labeled washout. If a C-section is scheduled in a pregnant patient who was on a GLP-1 before pregnancy was identified, the drug is already discontinued by definition. The relevant perioperative question is whether the patient resumed the drug; in practice the answer should always be no during pregnancy. See our piece on the GLP-1 8-week pregnancy washout for the labeled timing and the data underneath it.

Restarting the GLP-1 after surgery

The multisociety guidance^[2] recommends restarting once the patient is tolerating a regular oral diet, has no ileus, and is haemodynamically stable. Practical timing:

• Outpatient procedures (endoscopy, minor surgery): resume the next scheduled dose assuming normal recovery and no ongoing nausea.
• Inpatient elective surgery (cholecystectomy, hernia repair, joint replacement): resume 1–2 weeks postoperatively once eating and drinking normally.
• Bariatric surgery: per the bariatric team and the operation. Sleeve gastrectomy and gastric bypass patients often have GLP-1 effects from the surgery itself; the decision to restart is individualized.
• After a side-effect-driven hold: if the patient experienced significant nausea or gastroparesis-like symptoms in the days before surgery, coordinate with the prescribing clinician about restarting at a lower dose. The first few weeks of GLP-1 therapy are the highest-risk period for GI side effects regardless of restart timing — see our first 30 days survival guide for the dose-titration framework.

The practical perioperative checklist

1. Confirm GLP-1 use at every pre-op encounter. Surgical scheduling, anesthesia pre-op visit, day-of-surgery intake. Ask by brand name (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Rybelsus) and by category (compounded semaglutide, compounded tirzepatide, oral GLP-1).
2. Document the date of the last dose. The time interval drives the hold decision.
3. Apply the hold rule. Weekly drugs ≥ 7 days since last dose; daily drugs ≥ 24 hours.
4. Day-of-surgery symptom check. Nausea, vomiting, early satiety, abdominal distension, or dyspepsia in the preceding 24 hours all suggest delayed gastric emptying regardless of the dose interval. Re-categorize as full stomach if any of those are present.
5. Consider gastric ultrasound when the hold history is uncertain, when symptoms are present, or when expertise is available. A clear empty antrum is reassuring; visible solid content is a hard indication for full-stomach precautions.
6. Glucose plan for diabetes patients. Patients on a GLP-1 for type 2 diabetes need a coverage plan during the hold — usually basal insulin adjustment or short-acting insulin coverage. Coordinate with endocrinology or the prescribing clinician.
7. Document the restart plan in the discharge summary. Specify the date of the next allowable dose and any dose adjustment.

What this means for patients

If you are on a weekly GLP-1 and you have a procedure scheduled, the practical instruction is straightforward: skip the dose the week of surgery so your last injection is at least 7 days before the procedure. If you take Rybelsus or a daily injectable, skip the dose on the day of surgery. Tell every clinician involved in the procedure — surgeon, anesthesiologist, pre-op nurse, day-of-surgery nurse — that you are on a GLP-1. If you have been having nausea, vomiting, or feeling unusually full in the days leading up to surgery, tell the anesthesia team before induction. After the procedure do not restart on your own until you are eating and drinking normally; coordinate restart timing with the prescribing clinician, particularly if you had a longer recovery than expected.

Related research and tools

• GLP-1 as a bariatric surgery bridge — when GLP-1 is used to lose weight before bariatric surgery, and the operative timing it implies
• GLP-1 first 30 days survival guide — tolerability during dose escalation and restart timing after a perioperative hold
• GLP-1 rechallenge after pancreatitis — another perioperative-relevant decision for the same patient population
• GLP-1 8-week pregnancy washout — the labeled washout for pregnancy planning and its relevance to C-section anesthesia
• GLP-1 side-effect questions answered — the gastroparesis-symptom cluster that drives perioperative concern

Important disclaimer. This article is educational and does not constitute medical advice. Perioperative GLP-1 management decisions must be individualized and coordinated between the surgeon, the anesthesia team, and the prescribing clinician. Patients with type 1 diabetes or insulin-dependent type 2 diabetes who interrupt GLP-1 therapy need an active glucose management plan to reduce DKA risk. Patients with significant gastrointestinal symptoms on the day of surgery should be reassessed regardless of how long ago the last dose was taken. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 6 months while ASA, ASMBS, AGA, and ASGE guidance documents are evolving; sooner if a randomized comparison of hold durations is published.